Physostigmine and Arecoline: Effects of Intravenous Infusions in Alzheimer Presenile Dementia

Physostigmine (0.25 mg-1 mg), arecoline (2 and 4 mg) and saline were administered intravenously over 30 minutes in a randomized double blind design to 11 patients with a clinical diagnosis of Alzheimer presenile dementia. Significant improvement was seen on a picture recognition test with physostigm...

Full description

Saved in:
Bibliographic Details
Published in:British journal of psychiatry 1981-01, Vol.138 (1), p.46-50
Main Authors: Christie, J. E., Shering, A., Ferguson, J., Glen, A. I. M.
Format: Article
Language:English
Subjects:
Alzheimer Disease - drug therapy
Alzheimer Disease - psychology
Arecoline - therapeutic use
Clinical Trials as Topic
Dementia - drug therapy
Dose-Response Relationship, Drug
Double-Blind Method
Humans
Memory
Middle Aged
Physostigmine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Physostigmine (0.25 mg-1 mg), arecoline (2 and 4 mg) and saline were administered intravenously over 30 minutes in a randomized double blind design to 11 patients with a clinical diagnosis of Alzheimer presenile dementia. Significant improvement was seen on a picture recognition test with physostigmine 0.375 mg and arecholine 4 mg. A trend towards improvement was also seen with physostigmine 0.25 mg and 0.75 mg, and arecholine 2 mg. For the majority of the patients improvement was only slight but in two patients it was clear cut and consistent.
ISSN:0007-1250
1472-1465
DOI:10.1192/bjp.138.1.46